Skip to main content

Drug Interactions between glutamine and lovotibeglogene autotemcel

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

glutamine lovotibeglogene autotemcel

Applies to: glutamine and lovotibeglogene autotemcel

ADJUST DOSING INTERVAL: Sickle cell disease (SCD) modifying agents (e.g., crizanlizumab, voxelotor, and L-glutamine) may affect the manufacturing and therapeutic efficacy of the autologous genome edited hematopoietic stem cell-based gene therapy, lovotibeglogene autotemcel. The mechanism of this interaction is unknown. Hematopoietic stem cell mobilization is required to obtain the CD34+ cells needed for lovotibeglogene autotemcel production, followed by myeloablative conditioning prior to the lovotibeglogene autotemcel infusion. Clinical data on the interaction potential of crizanlizumab, voxelotor and L-glutamine with mobilization and conditioning agents are unavailable. Additionally, there are no available clinical data evaluating the use of crizanlizumab, voxelotor and L-glutamine after the administration of lovotibeglogene autotemcel.

MANAGEMENT: The manufacturer of lovotibeglogene autotemcel recommends the discontinuation of SCD modifying agents voxelotor, crizanlizumab and L-glutamine at least 2 months prior to the start of HSC mobilization, and at least 2 months prior to myeloablative conditioning. The manufacturer does not provide guidance on the use of SCD modifying agents after administration of the lovotibeglogene autotemcel infusion.

References

  1. (2023) "Product Information. Lyfgenia (lovotibeglogene autotemcel)." bluebird bio

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer